Immune-Mediated Retinal Vasculitis in Posterior Uveitis and Experimental Models: The Leukotriene (LT)B4-VEGF Axis

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2021 Mar 6

PMID 33671954

Citations 7

Authors

Malihe Eskandarpour

Miles A Nunn

Wynne Weston-Davies

Virginia L Calder

Affiliations

Soon will be listed here.

Abstract

Retinal vascular diseases have distinct, complex and multifactorial pathogeneses yet share several key pathophysiological aspects including inflammation, vascular permeability and neovascularisation. In non-infectious posterior uveitis (NIU), retinal vasculitis involves vessel leakage leading to retinal enlargement, exudation, and macular oedema. Neovascularisation is not a common feature in NIU, however, detection of the major angiogenic factor-vascular endothelial growth factor A (VEGF-A)-in intraocular fluids in animal models of uveitis may be an indication for a role for this cytokine in a highly inflammatory condition. Suppression of VEGF-A by directly targeting the leukotriene B4 (LTB4) receptor (BLT1) pathway indicates a connection between leukotrienes (LTs), which have prominent roles in initiating and propagating inflammatory responses, and VEGF-A in retinal inflammatory diseases. Further research is needed to understand how LTs interact with intraocular cytokines in retinal inflammatory diseases to guide the development of novel therapeutic approaches targeting both inflammatory mediator pathways.

Citing Articles

Long-term effects of tocilizumab on retinal and choroidal inflammation in Birdshot uveitis.

Zur Bonsen L, Schulze D, Kunzel S, Rubsam A, Pleyer U, Pohlmann D J Ophthalmic Inflamm Infect. 2024; 14(1):61.

PMID: 39570440 PMC: 11582289. DOI: 10.1186/s12348-024-00443-9.

Molecular and Cellular Mechanisms Involved in the Pathophysiology of Retinal Vascular Disease-Interplay Between Inflammation and Oxidative Stress.

Srejovic J, Muric M, Jakovljevic V, Srejovic I, Sreckovic S, Petrovic N Int J Mol Sci. 2024; 25(21).

PMID: 39519401 PMC: 11546760. DOI: 10.3390/ijms252111850.

Advancements in Ocular Therapy: A Review of Emerging Drug Delivery Approaches and Pharmaceutical Technologies.

Giri B, Jakka D, Sandoval M, Kulkarni V, Bao Q Pharmaceutics. 2024; 16(10).

PMID: 39458654 PMC: 11511072. DOI: 10.3390/pharmaceutics16101325.

Reply.

Matsumiya W, Karaca I, Pham B, Akhavanrezayat A, Uludag G, Yasar C Retina. 2024; 44(8):e53-e55.

PMID: 39047135 PMC: 11282323. DOI: 10.1097/IAE.0000000000004134.

AAV-mediated gene therapies for glaucoma and uveitis: are we there yet?.

Castro B, Steel J, Layton C Expert Rev Mol Med. 2024; 26:e9.

PMID: 38618935 PMC: 11062146. DOI: 10.1017/erm.2024.4.

References

Vinores S, Chan C, Vinores M, Matteson D, Chen Y, Klein D . Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. J Neuroimmunol. 1998; 89(1-2):43-50. DOI: 10.1016/s0165-5728(98)00075-7. View

Graham E, Stanford M, Shilling J, Sanders M . Neovascularisation associated with posterior uveitis. Br J Ophthalmol. 1987; 71(11):826-33. PMC: 1041319. DOI: 10.1136/bjo.71.11.826. View

Chen J, Wang W, Li Q . Increased Th1/Th17 Responses Contribute to Low-Grade Inflammation in Age-Related Macular Degeneration. Cell Physiol Biochem. 2017; 44(1):357-367. DOI: 10.1159/000484907. View

Elmasry K, Ibrahim A, Abdulmoneim S, Al-Shabrawey M . Bioactive lipids and pathological retinal angiogenesis. Br J Pharmacol. 2018; 176(1):93-109. PMC: 6284336. DOI: 10.1111/bph.14507. View

Konstan M, DORING G, Heltshe S, Lands L, Hilliard K, Koker P . A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros. 2014; 13(2):148-55. PMC: 4755340. DOI: 10.1016/j.jcf.2013.12.009. View

Zhu Y, Tan W, Demetriades A, Cai Y, Gao Y, Sui A . Interleukin-17A neutralization alleviated ocular neovascularization by promoting M2 and mitigating M1 macrophage polarization. Immunology. 2015; 147(4):414-28. PMC: 4799882. DOI: 10.1111/imm.12571. View

Serhan C, Chiang N, Dalli J . The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol. 2015; 27(3):200-15. PMC: 4515371. DOI: 10.1016/j.smim.2015.03.004. View

Jawad S, Liu B, Agron E, Nussenblatt R, Sen H . Elevated serum levels of interleukin-17A in uveitis patients. Ocul Immunol Inflamm. 2013; 21(6):434-9. PMC: 5569243. DOI: 10.3109/09273948.2013.815786. View

Diedrichs-Mohring M, Leban J, Strobl S, Obermayr F, Wildner G . A new small molecule for treating inflammation and chorioretinal neovascularization in relapsing-remitting and chronic experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2014; 56(2):1147-57. DOI: 10.1167/iovs.14-15518. View

10.

Liao T, Ke Y, Shao W, Haribabu B, Kaplan H, Sun D . Blockade of the interaction of leukotriene b4 with its receptor prevents development of autoimmune uveitis. Invest Ophthalmol Vis Sci. 2006; 47(4):1543-9. DOI: 10.1167/iovs.05-1238. View

11.

Suzuki H, Onishi H, Wada J, Yamasaki A, Tanaka H, Nakano K . VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur J Immunol. 2009; 40(1):197-203. DOI: 10.1002/eji.200939887. View

12.

Jiang S, Liu X, Luo L, Qu B, Huang X, Xu L . Elevated serum IL-23 correlates with intraocular inflammation after cataract surgery in patients with Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2009; 94(8):1078-82. DOI: 10.1136/bjo.2009.169052. View

13.

Martin D, Galisteo R, Gutkind J . CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem. 2008; 284(10):6038-42. PMC: 2649103. DOI: 10.1074/jbc.C800207200. View

14.

Merida S, Palacios E, Navea A, Bosch-Morell F . New Immunosuppressive Therapies in Uveitis Treatment. Int J Mol Sci. 2015; 16(8):18778-95. PMC: 4581271. DOI: 10.3390/ijms160818778. View

15.

Wildner G, Diedrichs-Mohring M . Resolution of uveitis. Semin Immunopathol. 2019; 41(6):727-736. DOI: 10.1007/s00281-019-00758-z. View

16.

Roversi P, Ryffel B, Togbe D, Maillet I, Teixeira M, Ahmat N . Bifunctional lipocalin ameliorates murine immune complex-induced acute lung injury. J Biol Chem. 2013; 288(26):18789-802. PMC: 3696655. DOI: 10.1074/jbc.M112.420331. View

17.

Lipski D, Foucart V, Dewispelaere R, Caspers L, Defrance M, Bruyns C . Retinal endothelial cell phenotypic modifications during experimental autoimmune uveitis: a transcriptomic approach. BMC Ophthalmol. 2020; 20(1):106. PMC: 7076950. DOI: 10.1186/s12886-020-1333-5. View

18.

Sezin T, Murthy S, Attah C, Seutter M, Holtsche M, Hammers C . Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. JCI Insight. 2019; 4(15). PMC: 6693894. DOI: 10.1172/jci.insight.128239. View

19.

Li Y, Zhou Y . Interleukin-17: The Role for Pathological Angiogenesis in Ocular Neovascular Diseases. Tohoku J Exp Med. 2019; 247(2):87-98. DOI: 10.1620/tjem.247.87. View

20.

Fang F, Chen D, Yu L, Dai X, Yang Y, Tian W . Proinflammatory stimuli engage Brahma related gene 1 and Brahma in endothelial injury. Circ Res. 2013; 113(8):986-96. PMC: 4049295. DOI: 10.1161/CIRCRESAHA.113.301296. View